Active ingredientBrilaroxazineCat. No. P-B108-001CAS 1239729-06-6Family · Pharmaceutical analytical standards
Brilaroxazine
An investigational third-generation antipsychotic that modulates dopamine and serotonin receptors: in schizophrenia it has completed a first phase III study, with results released in 2023, and it has also been studied for pulmonary arterial hypertension and idiopathic pulmonary fibrosis. This family brings together the active ingredient and other impurities.
Did you know?It is almost a twin of aripiprazole: the structure is identical except for one oxygen atom replacing a methylene group, which turns the quinolinone ring into a benzoxazinone.
Go to the active ingredient →Active ingredientBrilaroxazineCat. No. P-B108-001CAS 1239729-06-6
ImpurityBrilaroxazine Impurity 1Cat. No. P-B108-002CAS 1239729-01-1
ImpurityBrilaroxazine Impurity 2Cat. No. P-B108-003CAS 103942-21-8No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.